Lower Urinary Tract Symptoms: What’s New in Medical Treatment?

The document reviewed emerging evidence in the medical treatment of lower urinary tract symptoms (LUTS). Key innovations included the approval of the first β₃-adrenoceptor agonists (mirabegron) and intradetrusor onabotulinum toxin A for overactive bladder (OAB). Promising results were seen in phase 3 trials for other drugs like antiepileptics and phosphodiesterase inhibitors. Combination therapies of phosphodiesterase type 5 inhibitors with α-blockers or finasteride were found superior to single therapies. New formulations of desmopressin were approved for nocturia, and fedovapagon completed a large phase 3 trial for nocturia in males. Ongoing phase 3 trials were investigating treatments for bladder pain syndrome and neurogenic detrusor overactivity. The field of medical treatment for LUTS was very active, with several new and emerging drugs under investigation.